Liminatus Pharma Inc. (NASDAQ:LIMN) Stock Short Interest Drops 38.4%

Liminatus Pharma Inc. (NASDAQ:LIMN) saw a large decrease in short interest in the month of September. As of September 15th, there was short interest totaling 58,817 shares, a decrease of 38.4% from the August 31st total of 95,505 shares. Based on an average daily trading volume, of 27,526 shares, the short-interest ratio is presently 2.1 days. Currently, 5.4% of the company’s shares are short sold.

Analyst Ratings Changes

Several research firms have commented on LIMN. Weiss Ratings lowered shares of Liminatus Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Wall Street Zen lowered shares of Liminatus Pharma to a “strong sell” rating in a report on Saturday, August 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Liminatus Pharma presently has an average rating of “Sell”.

Liminatus Pharma Stock Up 2.5%

LIMN stock opened at $3.85 on Friday. Liminatus Pharma has a twelve month low of $3.29 and a twelve month high of $141.50. The firm has a market cap of $5.15 million, a price-to-earnings ratio of -0.16 and a beta of 4.95. The business’s fifty day simple moving average is $4.64 and its two-hundred day simple moving average is $7.01.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for serious diseases with significant unmet medical needs.

The company’s primary activities involve advancing pharmaceutical candidates through research and development, including preclinical and clinical testing. Publicly available information indicates that its work is centered on potential treatments in areas such as oncology and related therapeutic applications, rather than on marketed commercial products.

Liminatus Pharma is listed on the Nasdaq under the symbol LIMN.